Calcimedica Inc (CALC) Stock Price, Quote & News

Company Profile

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 952 5500

Website: calcimedica.com

Address:

505 Coast Boulevard South, Suite 307, La Jolla, United States

pablo4 May. 13 at 7:15 PM

$CALC has 2 catylysts very close by per the earnings PR: "FDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026"

0 · Reply

keokeostwiz May. 13 at 5:50 PM

$CALC Institutional buying today positive momentum moving forward.....looking for 1.25 next week

0 · Reply

66Caprice327 May. 13 at 5:49 PM

$CALC Won’t be providing any liquidity with my shares. This hasn’t even begun to get exciting. GL

0 · Reply

chop14 May. 13 at 5:49 PM

$CALC +9% but no volume. Risky

1 · Reply

MUBSN May. 13 at 5:24 PM

$CALC 6100 more, 80.000 total

0 · Reply

keokeostwiz May. 13 at 5:23 PM

$CALC Good News arriving by carrier pigeon SOON

1 · Reply

shoemaker74 May. 13 at 5:21 PM

$CALC Any good news?

0 · Reply

OffComesTheShirt May. 13 at 5:18 PM

$CALC 10% Off Comes The Shirt.

0 · Reply

keokeostwiz May. 13 at 5:12 PM

$CALC Catch a FIRE

0 · Reply

keokeostwiz May. 13 at 4:51 PM

$CALC Big bidder just bought 25k.....should be just the appetizer

0 · Reply

CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

2026-03-05T13:27:54.000Z - 2 months ago

CalciMedica price target lowered to $10 from $20 at Oppenheimer

2026-03-03T22:00:59.000Z - 2 months ago

CalciMedica files $125M mixed securities shelf

Mar 3, 2026, 7:00 AM EST - 2 months ago

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

2026-01-29T11:11:18.000Z - 3 months ago

CalciMedica downgraded to Neutral from Buy at H.C. Wainwright

Jan 28, 2026, 7:00 AM EST - 3 months ago

CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation

Nov 12, 2025, 7:01 AM EST - 6 months ago

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Nov 12, 2025, 7:00 AM EST - 6 months ago

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

Nov 10, 2025, 7:00 AM EST - 6 months ago

CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025

Oct 14, 2025, 7:00 AM EDT - 7 months ago

CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™

Sep 2, 2025, 7:00 AM EDT - 9 months ago

CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 7:00 AM EDT - 9 months ago

CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Jul 8, 2025, 7:00 AM EDT - 11 months ago

CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

Jun 25, 2025, 7:00 AM EDT - 11 months ago

CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure

Jun 12, 2025, 7:00 AM EDT - 11 months ago

CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting

May 14, 2025, 7:00 AM EDT - 1 year ago

CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Apr 17, 2025, 7:00 AM EDT - 1 year ago

CalciMedica Announces Presentations at Upcoming Medical Meetings

Apr 1, 2025, 7:00 AM EDT - 1 year ago

CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference

Mar 27, 2025, 7:00 AM EDT - 1 year ago

CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates

Mar 5, 2025, 7:00 AM EST - 1 year ago

CalciMedica Secures Credit Facility for Up to $32.5 Million

Mar 4, 2025, 7:00 AM EST - 1 year ago

CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference

Feb 19, 2025, 7:00 AM EST - 1 year ago

CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference

Feb 3, 2025, 4:05 PM EST - 1 year ago

CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 14, 2025, 7:00 AM EST - 1 year ago

CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors

Nov 21, 2024, 8:00 AM EST - 1 year ago

CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 13, 2024, 7:00 AM EST - 1 year ago

CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

Nov 7, 2024, 7:00 AM EST - 1 year ago

CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer

Oct 30, 2024, 10:11 PM EDT - 1 year ago

CalciMedica Announces Pricing of Public Offering of Common Stock

Oct 30, 2024, 4:50 PM EDT - 1 year ago

CalciMedica Announces Proposed Public Offering of Common Stock

Oct 30, 2024, 7:00 AM EDT - 1 year ago

CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

Oct 28, 2024, 4:05 PM EDT - 1 year ago

CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Oct 16, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

Sep 3, 2024, 8:00 AM EDT - 1 year ago

CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 12, 2024, 4:10 PM EDT - 1 year ago

CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

Jul 9, 2024, 7:30 AM EDT - 2 years ago

CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora™ in Severe Acute Kidney Injury (AKI)

Jul 8, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Announces Presentations at Two Upcoming Healthcare Investment Conferences

Jul 1, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Set to Join Russell Microcap® Index

Jun 27, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Jun 26, 2024, 4:05 PM EDT - 2 years ago

CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

May 13, 2024, 4:05 PM EDT - 2 years ago

CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

May 7, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024

Apr 24, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis

Mar 28, 2024, 7:00 AM EDT - 2 years ago

CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates

Mar 13, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Feb 28, 2024, 6:57 PM EST - 2 years ago

CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Feb 13, 2024, 8:00 AM EST - 2 years ago

CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury

Feb 7, 2024, 4:05 PM EST - 2 years ago

CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 22, 2024, 8:00 AM EST - 2 years ago

CalciMedica Announces Private Placement of up to Approximately $55 Million

Nov 9, 2023, 7:00 AM EST - 2 years ago

CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

Nov 2, 2023, 9:15 AM EDT - 2 years ago

CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition

Sep 6, 2023, 7:30 AM EDT - 2 years ago

CalciMedica Announces Upcoming Presentations and Events in September

Aug 31, 2023, 7:30 AM EDT - 2 years ago

CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023

Aug 9, 2023, 7:30 AM EDT - 3 years ago

CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

pablo4 May. 13 at 7:15 PM

0 · Reply

keokeostwiz May. 13 at 5:50 PM

$CALC Institutional buying today positive momentum moving forward.....looking for 1.25 next week

0 · Reply

66Caprice327 May. 13 at 5:49 PM

$CALC Won’t be providing any liquidity with my shares. This hasn’t even begun to get exciting. GL

0 · Reply

chop14 May. 13 at 5:49 PM

$CALC +9% but no volume. Risky

1 · Reply

MUBSN May. 13 at 5:24 PM

$CALC 6100 more, 80.000 total

0 · Reply

keokeostwiz May. 13 at 5:23 PM

$CALC Good News arriving by carrier pigeon SOON

1 · Reply

shoemaker74 May. 13 at 5:21 PM

$CALC Any good news?

0 · Reply

OffComesTheShirt May. 13 at 5:18 PM

$CALC 10% Off Comes The Shirt.

0 · Reply

keokeostwiz May. 13 at 5:12 PM

$CALC Catch a FIRE

0 · Reply

keokeostwiz May. 13 at 4:51 PM

$CALC Big bidder just bought 25k.....should be just the appetizer

0 · Reply

SUGONDEEZNUTS May. 13 at 4:46 PM

$CALC

0 · Reply

keokeostwiz May. 13 at 2:49 PM

$CALC That big bidder needs to get hungry and start hitting the ASK

0 · Reply

keokeostwiz May. 13 at 1:47 PM

$CALC 108.3k bid at .61....somebody wants in with a BIG appetite

0 · Reply

MUBSN May. 12 at 7:15 PM

$CALC what a pipeline!!

0 · Reply

Nousernam3 May. 12 at 6:22 PM

$CALC in for a 💯

0 · Reply

keokeostwiz May. 12 at 3:56 PM

$CALC Auxora P2b results establishing a strong foundation toward filling the void in AP and AKI unmet medical need areas critical in providing therapy to patients suffering from pancreatitis and kidney disease....the immediate targets for the company are FDA acceptance of P3 trial design and financing.....with positive P2b results supporting a strong clinical resume these objectives should be achieved in the second quarter setting the stage for the balance of 2026 success......JMO

1 · Reply

66Caprice327 May. 12 at 11:49 AM

$CALC Let her buck…

0 · Reply

ye81 May. 12 at 11:12 AM

$CALC https://finance.yahoo.com/sectors/healthcare/articles/calcimedica-reports-first-quarter-2026-110000015.html

0 · Reply

Action80gr May. 12 at 9:20 AM

$CALC Severe Hantavirus cases involve hyperinflammation, vascular leak & pulmonary edema — interesting overlap with Auxora’s CRAC inhibition mechanism. Not saying pipeline expansion, but scientifically worth watching given prior ARDS/acute lung injury focus. Could this be a future platform opportunity? $CALC

0 · Reply

MUBSN May. 9 at 1:31 PM

$CALC

0 · Reply

MUBSN May. 9 at 1:30 PM

$CALC

1 · Reply

MUBSN May. 9 at 1:28 PM

$CALC

0 · Reply

Market Cap	9.31M
Revenue (ttm)	0.00
Net Income (ttm)	-29.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-0.19

Volume	334,197
Avg Vol	291,684
Day's Range	N/A - N/A
Shares Out	15.74M
Stochastic %K	67%
Beta	0.85
Analysts	Strong Sell
Price Target	$10.33